Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 3670549 for cardioversion of atrial fibrillation
NL-OMON61456Phase 2Not yet recruiting
- Sponsor
- Bayer
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of BAY-3670549 in Atrial fibrillation (AFib), sponsored by Bayer. Primary endpoint: Conversion from atrial fibrillation to sinus rhythm within 3 hours. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
BAY-3670549
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NL-OMON61456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61456.